vs
C4 Therapeutics, Inc.（CCCC）与Finward Bancorp（FNWD）财务数据对比。点击上方公司名可切换其他公司
Finward Bancorp的季度营收约是C4 Therapeutics, Inc.的1.5倍（$16.5M vs $11.0M），Finward Bancorp净利率更高（12.0% vs -186.0%，领先198.0%），C4 Therapeutics, Inc.同比增速更快（112.8% vs 1.1%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs -19.1%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
Finward Bancorp是一家总部位于美国的区域性银行控股公司，主要面向本土运营区域内的个人消费者与中小企业，提供储蓄账户、各类贷款、商业融资及财富管理等零售与商业金融服务。
CCCC vs FNWD — 直观对比
营收规模更大
FNWD
是对方的1.5倍
$11.0M
营收增速更快
CCCC
高出111.7%
1.1%
净利率更高
FNWD
高出198.0%
-186.0%
两年增速更快
CCCC
近两年复合增速
-19.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $16.5M |
| 净利润 | $-20.5M | $2.0M |
| 毛利率 | — | — |
| 营业利润率 | -210.1% | 11.0% |
| 净利率 | -186.0% | 12.0% |
| 营收同比 | 112.8% | 1.1% |
| 净利润同比 | 40.7% | -5.6% |
| 每股收益（稀释后） | $-0.09 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCFNWD
| Q4 25 | $11.0M | $16.5M | ||
| Q3 25 | $11.2M | $17.4M | ||
| Q2 25 | $6.5M | $16.6M | ||
| Q1 25 | $7.2M | $15.5M | ||
| Q4 24 | $5.2M | $16.3M | ||
| Q3 24 | $15.4M | $14.9M | ||
| Q2 24 | $12.0M | $14.6M | ||
| Q1 24 | $3.0M | $25.3M |
净利润CCCCFNWD
| Q4 25 | $-20.5M | $2.0M | ||
| Q3 25 | $-32.2M | $3.5M | ||
| Q2 25 | $-26.0M | $2.2M | ||
| Q1 25 | $-26.3M | $455.0K | ||
| Q4 24 | $-34.6M | $2.1M | ||
| Q3 24 | $-24.7M | $606.0K | ||
| Q2 24 | $-17.7M | $143.0K | ||
| Q1 24 | $-28.4M | $9.3M |
营业利润率CCCCFNWD
| Q4 25 | -210.1% | 11.0% | ||
| Q3 25 | -306.4% | 20.5% | ||
| Q2 25 | -441.0% | 12.7% | ||
| Q1 25 | -402.9% | 4.0% | ||
| Q4 24 | -728.4% | 16.3% | ||
| Q3 24 | -183.9% | 2.7% | ||
| Q2 24 | -178.6% | 0.9% | ||
| Q1 24 | -1060.2% | 40.6% |
净利率CCCCFNWD
| Q4 25 | -186.0% | 12.0% | ||
| Q3 25 | -286.4% | 20.1% | ||
| Q2 25 | -402.6% | 12.9% | ||
| Q1 25 | -363.7% | 2.9% | ||
| Q4 24 | -667.8% | 12.9% | ||
| Q3 24 | -160.6% | 4.1% | ||
| Q2 24 | -147.6% | 1.0% | ||
| Q1 24 | -933.2% | 36.7% |
每股收益（稀释后）CCCCFNWD
| Q4 25 | $-0.09 | $0.46 | ||
| Q3 25 | $-0.44 | $0.81 | ||
| Q2 25 | $-0.37 | $0.50 | ||
| Q1 25 | $-0.37 | $0.11 | ||
| Q4 24 | $-0.50 | $0.50 | ||
| Q3 24 | $-0.35 | $0.14 | ||
| Q2 24 | $-0.26 | $0.03 | ||
| Q1 24 | $-0.41 | $2.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $174.7M |
| 总资产 | $359.1M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCFNWD
| Q4 25 | $74.6M | — | ||
| Q3 25 | $58.8M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $51.3M | — | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $59.6M | — | ||
| Q2 24 | $73.1M | — | ||
| Q1 24 | $89.7M | — |
股东权益CCCCFNWD
| Q4 25 | $256.6M | $174.7M | ||
| Q3 25 | $154.4M | $165.5M | ||
| Q2 25 | $174.1M | $154.3M | ||
| Q1 25 | $195.1M | $151.8M | ||
| Q4 24 | $216.0M | $151.4M | ||
| Q3 24 | $242.7M | $159.6M | ||
| Q2 24 | $247.1M | $148.6M | ||
| Q1 24 | $258.3M | $151.6M |
总资产CCCCFNWD
| Q4 25 | $359.1M | $2.0B | ||
| Q3 25 | $265.5M | $2.1B | ||
| Q2 25 | $296.5M | $2.1B | ||
| Q1 25 | $319.5M | $2.0B | ||
| Q4 24 | $349.6M | $2.1B | ||
| Q3 24 | $376.1M | $2.1B | ||
| Q2 24 | $381.1M | $2.1B | ||
| Q1 24 | $398.4M | $2.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $9.0M |
| 自由现金流率自由现金流/营收 | — | 54.8% |
| 资本支出强度资本支出/营收 | — | 5.2% |
| 现金转化率经营现金流/净利润 | — | 4.99× |
| 过去12个月自由现金流最近4个季度 | — | $10.6M |
8季度趋势，按日历期对齐
经营现金流CCCCFNWD
| Q4 25 | $-22.1M | $9.9M | ||
| Q3 25 | $-31.2M | $1.2M | ||
| Q2 25 | $-12.1M | $4.8M | ||
| Q1 25 | $-33.3M | $-3.8M | ||
| Q4 24 | $-17.9M | $9.8M | ||
| Q3 24 | $-24.1M | $-3.7M | ||
| Q2 24 | $-5.0M | $2.8M | ||
| Q1 24 | $-18.1M | $-25.0K |
自由现金流CCCCFNWD
| Q4 25 | — | $9.0M | ||
| Q3 25 | $-31.6M | $1.0M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | $-17.9M | $6.7M | ||
| Q3 24 | $-24.1M | $-4.2M | ||
| Q2 24 | $-5.2M | $1.1M | ||
| Q1 24 | — | $-736.0K |
自由现金流率CCCCFNWD
| Q4 25 | — | 54.8% | ||
| Q3 25 | -281.5% | 6.0% | ||
| Q2 25 | — | 27.0% | ||
| Q1 25 | — | -25.7% | ||
| Q4 24 | -346.5% | 41.2% | ||
| Q3 24 | -157.2% | -28.5% | ||
| Q2 24 | -43.1% | 7.6% | ||
| Q1 24 | — | -2.9% |
资本支出强度CCCCFNWD
| Q4 25 | — | 5.2% | ||
| Q3 25 | 3.7% | 0.9% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 0.1% | 18.8% | ||
| Q3 24 | 0.1% | 3.4% | ||
| Q2 24 | 1.6% | 11.2% | ||
| Q1 24 | 0.0% | 2.8% |
现金转化率CCCCFNWD
| Q4 25 | — | 4.99× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | -8.37× | ||
| Q4 24 | — | 4.66× | ||
| Q3 24 | — | -6.15× | ||
| Q2 24 | — | 19.23× | ||
| Q1 24 | — | -0.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
